Factors driving healthcare costs in the US
Health care costs in the US touched a staggering $3.2 trillion in 2015, which makes it one of the nation’s […]
Health care costs in the US touched a staggering $3.2 trillion in 2015, which makes it one of the nation’s […]
Developing nations offer welcoming and growing markets as Abbott focuses exclusively on reformulating and marketing off-patent medications Driven by patient
Branded Generics Promise Profits for Drugmakers, Peace of Mind for Patients Read Post »
As pharmaceutical companies face ceaseless pressure to expedite products to market, strategies for improving the drug development and manufacturing process
Optimizing your API strategy to deliver desired results Read Post »
Originally published by Er J. Wouters, Panos G. Kavanos, Martin McKee in The Milbank Quarterly, 95: 554–601 under a Creative Commons License.
This article was originally published by Ekaterina Galkina Cleary, Jennifer M. Beierlein, Navleen Surjit Khanuja, Laura M. McNamee and Fred D.
Contribution of NIH funding to new drug approvals 2010–2016 Read Post »
Without a strong biosimilars market, costs for biologics in the US continue trending upward. The world of drug patents for
Formularies come into effect at the hospital level and the individual insurer level When developed and managed with due care
Formulary Decisions: Exploring the Ethics of Drug Approval Read Post »
MAKE BETTER DECISIONS Join the 500+ leading biopharmaceutical companies we have served and make better decisions with DrugPatentWatch’s deep knowledge
Although currently tiny and narrowly focused on a handful of disease areas and countries, the biosimilar industry is set to